Bausch + Lomb Corporation (BLCO)

In the past six months, Bausch + Lomb's stock has been influenced by several events, including Q3 2025 earnings report with an EPS of $0.18 and quarterly revenue rose 7.1% year-over-year to $1.28 billion. Bausch Health Companies Inc. explored a potential sale of its 88% interest in Bausch + Lomb but ultimately decided not to proceed. In Q1 2025, Bausch + Lomb's stock fell after reporting lower-than-expected financials and trimming its full-year growth outlook due to unfavorable foreign exchange changes and a recall of its enVista-branded intraocular lenses. The stock has seen a 7.6% rise since September 2025, outperforming the S&P 500, and as of January 2026, the stock was trading near the higher end of its 52-week range.

The medical devices industry, in which Bausch + Lomb operates, generally experiences steady demand. The nature of eye health products and medical devices often suggests a relatively consistent demand driven by ongoing healthcare needs rather than pronounced seasonal patterns.

Bausch + Lomb Corp. is a global eye health company established in 1853, focusing on protecting and enhancing sight. The company operates in the healthcare sector, specifically in the medical instruments and supplies industry. Bausch + Lomb's business is segmented into Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment includes contact lenses, lens care products, and consumer eye care products. The Ophthalmic Pharmaceuticals segment provides prescription medications for various eye conditions. The Surgical segment offers medical device equipment, consumables, and technologies for treating cataracts, corneal, vitreous, and retinal eye conditions.

Bausch + Lomb has a significant global presence, with operations in nearly 100 countries. The company operates in numerous international markets, including the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, and Poland.

Bausch + Lomb has been recognized for its innovation and commitment to eye health as of 2023. The company's brand reputation in the past year has been supported by strong demand for its dry eye products and the launch of MIEBO, as well as surgical consumables, which contributed to revenue growth across all segments in Q3 2025. However, a product recall of its enVista-branded intraocular lenses in Q1 2025 did impact its financials and led to a trimmed full-year growth outlook.

Bausch Health Companies Inc. is the majority owner of Bausch + Lomb, holding an 87.65% interest. Major institutional shareholders include Deutsche Bank AG, Icahn Carl C, Oaktree Capital Management LP, Goldentree Asset Management LP, D. E. Shaw & Co., Inc., Silver Point Capital L.P., Fmr Llc, Glenview Capital Management, Llc, and Nomura Holdings Inc.